Drug intelligence / Profile preview

HEA125 + OKT3

Development stage
Preclinical
Lead developer
Johnson & Johnson
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

HEA125 + OKT3 is a combination of two monoclonal antibodies. OKT3 (muromonab-CD3) is a murine-derived monoclonal antibody that targets the CD3 receptor complex on human T cells, resulting in rapid depletion or modulation of peripheral T cells and profound immunosuppression[2][5][9]. It was primarily used to reverse acute organ transplant rejection. HEA125, according to available references, is another monoclonal antibody, but publicly available clinical information specifically detailing its molecular target, mechanism, or clinical status is lacking; published work identifies it as an anti-EpCAM (epithelial cell adhesion molecule) monoclonal antibody in certain research, but this is not fully established in current pharmaceutical data. The combination is most likely experimental, aiming to combine T cell depletion (via OKT3) with additional immunomodulatory or tumor-targeting effects (via HEA125, potentially anti-EpCAM), possibly for enhanced anti-tumor effects or improved immunosuppression, paralleling recent strategies that combine anti-CD3 and other T cell-redirecting or tumor-targeting antibodies[6].

Brand names
Orthoclone OKT3
Other names
muromonab-cd3muromonab-cd-3muromonab-cd 3HEA125HEA-125HEA 125
02

Targets

EPCAM (Epithelial cell adhesion molecule)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on HEA125 + OKT3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEA125 + OKT3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call